Reimbursed Care Access in Israel

Israel currently permits psilocybin only within formal clinical research and limited compassionate/research programs; there is no routine reimbursed outpatient psilocybin medicine pathway. Multiple Israeli university and hospital sites have active or recently expanded phase 2 and earlier clinical trials evaluating psilocybin for major depressive disorders and PTSD — these trials require Ministry of Health (MoH) approvals and Institutional Review Board oversight and patients access psilocybin only as trial participants. #. ([rss.globenewswire.com](https://rss.globenewswire.com/news-release/2025/06/12/3098559/0/en/Apex-Labs-Granted-Israel-MoH-Approval-to-Expand-Phase-2b-Macrodose-Psilocybin-PTSD-Clinical-Trial.html?utm_source=openai))

Clinical access outside trials is extremely limited and generally requires participation in an MoH‑approved research protocol or a specific compassionate/research authorization; there is no established national reimbursement pathway analogous to a marketed prescription drug or inclusion in the national “health basket.” Institutions running trials typically provide the drug and clinical care under the research budget or specific program funding, not via routine HMO pharmacy coverage. ([rss.globenewswire.com](https://rss.globenewswire.com/news-release/2025/06/12/3098559/0/en/Apex-Labs-Granted-Israel-MoH-Approval-to-Expand-Phase-2b-Macrodose-Psilocybin-PTSD-Clinical-Trial.html?utm_source=openai))

MDMA‑assisted psychotherapy in Israel has been enabled through regulated clinical research and a historic compassionate‑use program rather than a licensed, reimbursed medicine available in routine psychiatric practice. In February 2019 the Israeli Ministry of Health approved a Compassionate Use program for MDMA‑assisted psychotherapy for PTSD (an explicitly limited program originally intended for a finite number of patients and administered at designated clinical sites), and Israeli sites have also participated in multinational Phase 3 trials run by MAPS. #. ([maps.org](https://maps.org/2020/02/26/press-release-israel-embraces-research-on-mdma-assisted-psychotherapy-for-ptsd/?utm_source=openai))

Operationally, access in Israel is therefore: (1) via enrollment in MoH/IRB‑approved clinical trials (sites coordinated with MAPS and local research centers), or (2) via tightly controlled compassionate‑use/expanded‑access pathways authorized by the Ministry of Health. These programs are delivered in supervised clinic settings with certified therapists; MDMA is not a pharmacy prescription drug patients can obtain through the HMO drug basket, and there is no broad private or public reimbursement pathway for MDMA outside those sanctioned research/compassionate frameworks. ([maps.org](https://maps.org/2020/02/26/press-release-israel-embraces-research-on-mdma-assisted-psychotherapy-for-ptsd/?utm_source=openai))

Esketamine (marketed as Spravato) is registered and listed in Israeli drug references and is used clinically for treatment‑resistant depression under the product’s approved indications; it is administered under supervised clinic protocols and subject to the manufacturer/health‑system distribution requirements. Israeli drug databases list Spravato with dosing indications for adults with treatment‑resistant major depressive disorder, consistent with the product labeling used internationally. #. ([medic.co.il](https://medic.co.il/drug/spravato/?utm_source=openai))

Reimbursement and coverage: Spravato in Israel is delivered through clinical programs and may be subject to partial coverage mechanisms (special authorizations, limited inclusion in HMO services, or private payment) rather than universal automatic coverage in the national ‘health basket.’ Cost and coverage frequently depend on HMO (kupat cholim) policies, individual authorization forms, and whether the treatment is delivered in a public hospital versus a private clinic; patient out‑of‑pocket costs and need for supplemental insurance or manufacturer assistance programs are commonly reported in clinical practice. #. ([medic.co.il](https://medic.co.il/drug/spravato/?utm_source=openai))

Ketamine is widely used in Israel for psychiatric indications on an off‑label basis (for example, treatment‑resistant depression, PTSD, suicidality and other indications) and is available through both public hospital programs and private ketamine clinics. The Ministry of Health permits use of licensed medications off‑label with appropriate medical authorization; clinics and hospital programs offer IV infusions, intramuscular dosing, and ketamine‑assisted psychotherapy models. Several specialized public programs were established (including subsidized public treatments addressing trauma from large‑scale events) while private clinics offer outpatient infusion and KAP services — private clinics generally bill patients directly, sometimes providing superbills for partial reimbursement claims. #; #. ([acptisrael.com](https://acptisrael.com/en/elementor-2406/?utm_source=openai))

Reimbursement nuance: ketamine for psychiatric indications is typically handled as an off‑label use of an approved anesthetic; routine inclusion in the national health basket is limited. Individual public programs (e.g., hospital‑led trauma/PTSD programs) may be publicly funded for eligible patients and require formal referrals and MoH/HMO documentation (Form 17 and other administrative filings are used in practice), while most private infusion/KAP services operate on a self‑pay basis or through supplemental insurance/individual authorizations — reimbursement is therefore variable and frequently requires case‑by‑case HMO approval or clinical trial funding. #; #. ([acptisrael.com](https://acptisrael.com/en/elementor-2406/?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. ([psilocybinalpha.com](https://www.psilocybinalpha.com/data/worldwide-psychedelic-laws?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. ([psilocybinalpha.com](https://www.psilocybinalpha.com/data/worldwide-psychedelic-laws?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. ([psilocybinalpha.com](https://www.psilocybinalpha.com/data/worldwide-psychedelic-laws?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Note: while international conventions treat DMT as controlled, the legal status of plant brews can vary by country; in Israel, ayahuasca use is not an established legal medical pathway and prosecutions/defenses have arisen in practice. ([psilocybinalpha.com](https://www.psilocybinalpha.com/data/worldwide-psychedelic-laws?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Peyote/mescaline plant legal exceptions that exist in some countries do not provide a routine medical access pathway in Israel.) ([psilocybinalpha.com](https://www.psilocybinalpha.com/data/worldwide-psychedelic-laws?utm_source=openai))

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Synthetic phenethylamine analogues such as 2C‑I/2C‑B have been specifically controlled in Israel in prior regulatory actions.) ([erowid.org](https://www.erowid.org/chemicals/2ci/2ci_law.shtml?utm_source=openai))